autologous cultured chondrocytes on porcine collagen membrane · Maci

Cell therapy

Approved / Phase 4Mechanism not established
Approvedregulatory verdict

Evidence outlook

Approved: Cartilage Defects of the Knee

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT06915233 · Vericel Corporation
2026-05-28 – 2030-07 · Chondral Defect, Articular Cartilage Defect
What this study did
NCT03588975 · Vericel Corporation
2018-10-24 – 2030-02 · Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Maci (autologous cultured chondrocytes on porcine collagen membrane) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (2)
February 2030 (1)
Phase 3Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of KneeRecruiting
Est. primary completion 2030-02 · NCT03588975 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Chondral Defect, Articular Cartilage DefectRecruiting
Est. primary completion 2030-07 · NCT06915233 · CT.gov ↗
What to watch

See the full readout calendar ↗